Brief: Astellas - Us FDA Approves Padcev Plus Keytruda As Neoadjuvant And Adjuvant Treatment For Muscle-Invasive Bladder Cancer Regardless Of Cisplatin Eligibility
13/07/2026 05:16
BRIEF-Astellas - Us FDA Approves Padcev Plus Keytruda As Neoadjuvant And Adjuvant Treatment For Muscle-Invasive Bladder Cancer Regardless Of Cisplatin Eligibility July 13 (Reuters) - Astellas Pharma Inc 4503.T:
ASTELLAS: US FDA APPROVES PADCEV PLUS KEYTRUDA AS NEOADJUVANT AND ADJUVANT TREATMENT FOR MUSCLE-INVASIVE BLADDER CANCER REGARDLESS OF CISPLATIN ELIGIBILITY
Source text: [ID:]
Further company coverage: 4503.T
(Reporting by Tokyo Newsroom)
((+81345201189;))
Recent news on Astellas Pharma
See all newsBrief: Immuneering To Collaborate With Astellas On Clinical Studies Of Investigational CLDN18.2 Programs In Combination With Atebimetinib For Pancreatic Cancer Patients
Health Rounds: New blood test finds early risk for ovarian cancer
Health Rounds: New blood test finds early risk for ovarian cancer
Refile: Astellas employee imprisoned in China to be released in December, Japanese media report
Table: Astellas Pharma -6-MTH group results (IFRS)